Free Alerts   Login
Health Care › Pharmaceutical Preparations

MRSN Stock Price Correlated With Mersana Therapeutics Financials

MRSN Stock Price vs. Quarterly
MRSN
Income Statement
Cash Flow
Balance Sheet

MRSN Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

MRSN Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

MRSN Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Ecor1 Capital
19,364,688 sh
19,364,688 sh
NEW
$44,926
$44,926
Vr Adviser
11,328,000 sh
11,328,000 sh
NEW
$26,281
$26,281
Balyasny Asset Management
9,698,147 sh
4,657,247 sh
92%
$22,500
$16,098
Bain Capital Life Sciences Investors
8,663,673 sh
 
$20,100
Blackrock.
7,844,282 sh
-128,378 sh
-2%
$18,199
$8,074
SILVERARC CAPITAL MANAGEMENT
6,420,136 sh
5,618,536 sh
701%
$14,895
$13,877
Vanguard Group
6,237,588 sh
51,465 sh
1%
$14,472
$6,616
Nextech Invest AG
5,978,327 sh
5,978,327 sh
NEW
$13,870
$13,870
Morgan Stanley
4,134,546 sh
3,148,529 sh
319%
$9,591
$8,339
Millennium Management
3,394,440 sh
1,216,790 sh
56%
$7,875
$5,109
Rock Springs Capital Management Lp
3,046,782 sh
-356,351 sh
-10%
$7,069
-$4,127
Acuta Capital Partners
2,368,000 sh
2,368,000 sh
NEW
$5,494
$5,494
State Street
2,329,434 sh
16,692 sh
1%
$5,404
$2,467
Geode Capital Management
2,297,136 sh
139,471 sh
6%
$5,330
$2,589
Citadel Advisors
1,926,931 sh
1,878,631 sh
3890%
$4,470
$4,409
5am Venture Management
1,305,000 sh
 
$3,028
Philosophy Capital Management
1,264,567 sh
1,264,567 sh
NEW
$2,934
$2,934
Schonfeld Strategic Advisors
1,139,407 sh
1,089,407 sh
2179%
$2,643
$2,633
Deutsche Bank Ag\
1,139,232 sh
1,076,405 sh
1713%
$2,643
$2,564
Baker Bros. Advisors Lp
1,086,115 sh
 
$2,520

Free historical financial statements for Mersana Therapeutics Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 24 quarters since 2018. Compare with MRSN stock chart to see long term trends.

Data imported from Mersana Therapeutics Inc SEC filings. Check original filings before making any investment decision.